Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anthony Defelice

Orthopaedic Trauma Pittsfield, MA Doctor of Osteopathy

NPI 1902831043 CMS profile 176588

24 Park Street, Pittsfield, MA 01201

Open in the dashboard

General payments

$3,323

25 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anthony Defelice of Pittsfield, MA is reported in the CMS Open Payments database as having received $3,323 across 25 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 30th percentile of Orthopaedic Trauma profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $182 3
2024 General $1,909 8
2023 General $1,134 11
2019 General $97 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anthony Defelice
  • Orthopaedic Trauma median
  • Middle half of Orthopaedic Trauma
  • National median

In program year 2025, general payments to Anthony Defelice were reported at $182. Among 734 Orthopaedic Trauma profiles paid that year, the median was $1,227 and the middle half received between $259 and $7,433.

Show as a table
Year Anthony Defelice Orthopaedic Trauma median Middle half National median
2019 $97 $1,475 $264–$6,401 $163
2020 $0 $596 $120–$4,020 $114
2021 $0 $919 $171–$4,697 $132
2022 $0 $1,547 $272–$7,240 $149
2023 $1,134 $1,330 $247–$5,875 $160
2024 $1,909 $1,288 $277–$6,797 $164
2025 $182 $1,227 $259–$7,433 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $1,998 10 payments
  2. DePuy Synthes Sales Inc. $942 6 payments
  3. Medical Device Business Services, Inc. $225 4 payments
  4. Brainlab, Inc. $59 1 payment
  5. Medtronic, Inc. $44 1 payment
  6. Vericel Corporation $21 1 payment
  7. Pacira Pharmaceuticals Incorporated $17 1 payment
  8. Bioventus LLC $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $2,471 8 payments
  2. Food and Beverage $830 16 payments
  3. Education $21 1 payment
Products named General payments · program years 2019–2025
  1. FIRSTPASS $1,888 7 payments
  2. ACUFEX Meniscal Root Repair $1,888 7 payments
  3. NovoStitch $1,095 6 payments
  4. Velys $921 5 payments
  5. TFN-Advance $125 1 payment
  6. ATTUNE $100 3 payments
  7. Bone Anchors with Arthroscopic Delivery System $75 1 payment
  8. HEALICOIL $75 1 payment
  9. SOLITAIRE X $44 1 payment
  10. Bioinductive Implant with Arthroscopic Delivery System - Medium $22 1 payment
  11. Other $145 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 96 billing codes

Paid by Medicare

$316,943

Of which drugs: $48,416

Medicare patients

875

Average age 74

Services billed

12,720

547 women, 328 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 73%
High blood pressure 69%
Diabetes 26%
Depression 24%
Ischemic heart disease 23%
Osteoporosis 20%
COPD 18%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 70 7,080 $36,475
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 284 1,653 $8,847
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 38 294 $223

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

25 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Trauma in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record